Loading stock data…
$20.55-0.92 (-4.29%)
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Mineralys Therapeutics, Inc. in the Healthcare sector is trading at $20.55 with a market capitalization of $2.5B. Wall Street consensus targets $46.33 (9 analysts), implying a +125.5% move over the next 12 months. The stock is currently near its 52-week low of $20.12, remaining 24.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$246.04M↓ | -$45.34M↓ | -$38.28M↑ | -$41.13M↑ | -$46.75M |
| Net Income | -$241.07M↓ | -$39.34M↓ | -$32.23M↑ | -$36.93M↑ | -$43.27M |
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone ...